Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Impulse Control Disorders in Parkinson's Disease
NCT03947216Phase 2Completed
- Sponsor
- Strasbourg University Hospital
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in impulse control disorders (ICD) comparing PIMAVANSERIN with PLACEBO (2 arms). Primary endpoint: Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale at 8 weeks. Started Oct 2020; status: completed.
02
Drugs
pimavanserin
03
Conditions
impulse control disorders (ICD)
Beyond the preview
Go deeper on NCT03947216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947216.